Prostate cancer is a significant source of morbidity and mortality in the West, and remains the second leading cause of death from a solid malignancy in men in the United States.1 However, its effect on populations in the Middle East and North Africa (MENA) region is not completely known. A prostate cancer committee was established to modify the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Prostate Cancer for adaptation and implementation in the MENA region. The objective was to enhance the multidisciplinary approach to the treatment of prostate cancer. The committee, comprising regional experts in the fields of urologic, medical, and radiation oncology, reviewed the 2009 version of the NCCN Guidelines on Prostate Cancer and suggested modifications based on the unique needs of the region determined through published evidence and local expertise. The committee identified several areas in the NCCN Guidelines that they believed required modification, which are presented in this article. The treatment of prostate cancer in the MENA region has numerous challenges. The hope is that this effort to modify the NCCN Guidelines on Prostate Cancer for practical use in the MENA region will improve regional awareness and patient care.
Young JL. Cancer incidence in the Middle East and Gulf Cooperation Council countries. Presented at the Middle East Cancer Consortium Steering Committee Meeting; January 20, 2003; Lyon, France.
Shamseddine A, Sibai AM, Gehchan N et al.. Cancer incidence in postwar Lebanon: findings from the first national population-based registry, 1998. Ann Epidemiol 2004;14:663–668.
Bianco FJ Jr, Riedel ER, Begg CB et al.. Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol 2005;173:2099–2103.
International Atomic Energy Agency. Directory of Radiotherapy Centres. Available at: http://www-naweb.iaea.org/nahu/dirac/default.asp. Accessed March 31, 2010.
Smith DC, Redman BG, Flaherty LE et al.. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52:257–260.